BECLOVENT
LOE ApproachingNDAINHALATIONAEROSOL, METERED
Approved
Jun 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BECLOVENT is a metered-dose aerosol inhaler approved in 1980 containing an unknown active pharmaceutical ingredient. The drug is indicated for inhalation therapy, though specific indications are not documented in available data. As a small molecule delivered via respiratory route, it represents a classic inhaled therapeutic modality.
LOE Approaching
This legacy product is approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting a contracting team focused on margin protection rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
BECLOVENT currently has zero linked job openings, reflecting its LOE-approaching status and mature market position. Career opportunities on this product are limited to maintenance roles in commercial execution and regulatory compliance rather than growth or innovation tracks.
Brand Manager (Legacy)Regulatory Affairs Specialist
Worked on BECLOVENT at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.